China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
HAIKOU, China, Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that through Hainan Helpson Medical an...
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
HAIKOU, China, Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effectiveWednesday, March 6, 2024, with trading to begin on a split-adjusted basi...
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its Dry Eye Disease (DED) therape...
China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs
HAIKOU, China, Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. (hereinafter referred to as ...
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
HAIKOU, China, Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveMonday, March 6, 2023, with trading to begin on a split-adjusted basis ...
China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask
HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the launch of N95 medical protect...
China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19
HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its drugs were listed in The...
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the Acquisition of Dry Eye Disease...
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China, Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onDecember 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NY...
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency
HAIKOU, China, Oct. 1, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that onSeptember 26, 2022, the Company received notification (the "Deficiency Letter") from the NYSE AMERICAN LLC ("NYSE American") informing it that the Company is not in ...
China Pharma Announced the Submission of a Plan of Compliance to NYSE American
HAIKOU, China, July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onJuly 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the...
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China, June 22, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onJune 15, 2022, the Company received a letter from NYSE American LLC ("NYSE American" or the "Exchange"...
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the fiscal...
China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...
China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
HAIKOU, China, Aug. 13, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
HAIKOU, China, Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the result...
China Pharma to Launch Highly Purified NMN+PQQ Product
HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale ...
China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue
HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2021. Revenue increased by 33.7% to $2.4 million for the thr...
China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port
HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...
China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results
HAIKOU CITY, China, March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the ...
